^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HLA-A2 positive

    i
    Other names: HLA-A, Major Histocompatibility Complex, Class I, A, HLA Class I Histocompatibility Antigen, A Alpha Chain, HLAA, HLA Class I Histocompatibility Antigen, A-1 Alpha Chain, MHC Class I Antigen HLA-A Heavy Chain, Leukocyte Antigen Class I-A, Human Leukocyte Antigen A
    Entrez ID:
    3105
    Related biomarkers:
    Expression
    Mutation
    Others
    12ms
    Enhancing HBV-specific T cell responses through a combination of epigenetic modulation and immune checkpoint inhibition. (PubMed, Hepatology)
    The combination of DAC/αPD-L1 shows promise in improving HBV-specific T cell responses in vitro, highlighting the potential of remodeling exhaustion-associated epigenetic signatures to enhance HBV-specific T cell restoration and suggesting a novel immunotherapeutic avenue for CHB.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
    |
    HLA-A*02 • HLA-A2 positive
    |
    decitabine
    12ms
    ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Ovarian Cancer (SURPASS-3) (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, Adaptimmune | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • BRCA (Breast cancer early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression
    |
    Opdivo (nivolumab) • uzatresgene autoleucel (ADP-A2M4CD8)
    1year
    TEDOVA: OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC (clinicaltrials.gov)
    P2, N=180, Active, not recruiting, ARCAGY/ GINECO GROUP | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    HLA-A2 positive • HLA-A positive
    |
    Keytruda (pembrolizumab) • Tedopi (OSE 2101)
    1year
    Safety and Tolerability of Letetresgene Autoleucel (Lete-cel; GSK3377794): Pilot Studies in Patients With Advanced Non-Small Cell Lung Cancer. (PubMed, Clin Cancer Res)
    Extensive HLA-A*02 and antigen expression testing was performed to identify potential participants. Lete-cel was generally well tolerated and had no unexpected AEs. Anti-tumor activity was observed in a limited number of patients.
    Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
    |
    HLA-A*02:01 • HLA-A*02 • HLA-A2 positive • HLA-A positive
    |
    Keytruda (pembrolizumab) • letetresgene autoleucel (GSK3377794)
    1year
    Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, Adaptimmune | Trial completion date: Jul 2024 --> Jul 2025
    Trial completion date • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B)
    |
    HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive
    |
    cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)
    1year
    Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HLA-A2 positive
    |
    Imfinzi (durvalumab) • Hiltonol (poly-ICLC) • PVX-410
    over1year
    ZENYTH-ESO: Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=12, Terminated, GlaxoSmithKline | Trial completion date: Dec 2025 --> Jun 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Jun 2023; The study was terminated due to a change in GSK's R&D priorities.
    Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
    |
    HLA-A*02:01 • HLA-A*02 • HLA-A2 positive • CTAG2 expression
    |
    cyclophosphamide • fludarabine IV • GSK3845097 • GSK3901961 • LYL132
    over1year
    IGNYTE-ESO: Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (clinicaltrials.gov)
    P2, N=103, Active, not recruiting, Adaptimmune | Trial primary completion date: Nov 2022 --> Aug 2024
    Trial primary completion date • Combination therapy
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B)
    |
    HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive
    |
    cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)
    over1year
    ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2) (clinicaltrials.gov)
    P2, N=3, Terminated, Adaptimmune | N=45 --> 3 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Apr 2023; Study was terminated due to difficulty recruiting subjects and lack of efficacy
    Enrollment change • Trial termination • Trial primary completion date • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02 • HLA-A2 positive • MAGEA4 expression
    |
    uzatresgene autoleucel (ADP-A2M4CD8)
    over1year
    Human Immune Responses to Yellow Fever Vaccination (clinicaltrials.gov)
    P4, N=250, Recruiting, Emory University | Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02 • HLA-A2 positive
    over1year
    HPV16 E6 TCR T Cells for Cervical Carcinoma (clinicaltrials.gov)
    P1/2, N=18, Recruiting, TCRCure Biopharma Ltd. | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    HLA-A2 positive
    |
    cyclophosphamide • fludarabine IV
    almost2years
    H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas (clinicaltrials.gov)
    P1/2, N=50, Completed, Sabine Mueller, MD, PhD | Active, not recruiting --> Completed | Trial completion date: Nov 2024 --> Dec 2023 | Trial primary completion date: Nov 2024 --> Dec 2023
    Trial completion • Trial completion date • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02:01 • H3.3K27M • HLA-A*02 • HLA-A2 positive
    |
    Opdivo (nivolumab) • Hiltonol (poly-ICLC)